Quviviq

Quviviq is the brand name for the prescription drug daridorexant, a dual orexin receptor antagonist approved for the treatment of insomnia in adults. As a DORA, it blocks orexin A and orexin B signaling at the OX1R and OX2R receptors in the hypothalamus, reducing wake-promoting activity and promoting sleep onset and maintenance.

Quviviq was developed by Idorsia. After clinical trials demonstrated improvements in sleep latency and total sleep time, daridorexant received regulatory approval in several regions in the early 2020s. The medication is intended for adult patients with insomnia and is taken orally, typically once daily in the evening, with dosing determined by a clinician based on response and tolerability.

Common adverse effects reported with Quviviq include daytime sleepiness, headache, dizziness, and fatigue. As with other sleep aids, patients should avoid driving or operating heavy machinery until they know how the medication affects them, and should limit or avoid alcohol and other central nervous system depressants. Quviviq is not indicated for pediatric use and should be used with caution in individuals with liver impairment or other significant comorbidities. Clinicians may consider potential drug interactions, particularly with strong CYP3A inhibitors or inducers, which can alter daridorexant levels.

Overall, Quviviq represents a non-benzodiazepine option for adult insomnia, targeting wake-promoting orexin pathways rather than broadly depressing the central nervous system.